Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
An update from Cara Therapeutics ( (CARA) ) is now available.
Cara Therapeutics has entered into a merger agreement with Tvardi Therapeutics to form a new Nasdaq-listed company focusing on developing STAT3 inhibitors to treat fibrosis-driven diseases. This strategic merger includes significant changes in leadership and ownership, with Tvardi’s executives leading the combined company and its investors holding a majority stake, and is expected to provide the necessary funding to advance clinical trials and product development efforts.
More about Cara Therapeutics
Cara Therapeutics is a biopharmaceutical company that focuses on developing treatments for fibrosis-driven diseases. Their primary offerings include small molecule therapies targeting the STAT3 protein, with a significant market focus on addressing unmet medical needs in this area.
YTD Price Performance: -65.14%
Average Trading Volume: 540,151
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $13.7M
Find detailed analytics on CARA stock on TipRanks’ Stock Analysis page.
